Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Entera Bio Ltd. stock logo
ENTX
Entera Bio
$1.83
+1.1%
$1.94
$1.50
$2.79
$82.65M1.6980,277 shs44,907 shs
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
$0.77
$0.77
$0.67
$3.77
$3.37M1.12N/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$0.97
+0.3%
$1.74
$0.79
$6.98
$43M0.487.39 million shs521,191 shs
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
$4.21
$4.40
$3.03
$5.76
$5.60M1.4184,502 shs3,917 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Entera Bio Ltd. stock logo
ENTX
Entera Bio
+1.10%+0.55%-5.67%-7.11%-4.19%
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.00%0.00%0.00%0.00%-2.67%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
+0.33%-10.07%-63.76%-46.04%-82.59%
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
+0.38%-3.79%-12.82%-3.44%-20.27%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Entera Bio Ltd. stock logo
ENTX
Entera Bio
$1.83
+1.1%
$1.94
$1.50
$2.79
$82.65M1.6980,277 shs44,907 shs
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
$0.77
$0.77
$0.67
$3.77
$3.37M1.12N/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$0.97
+0.3%
$1.74
$0.79
$6.98
$43M0.487.39 million shs521,191 shs
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
$4.21
$4.40
$3.03
$5.76
$5.60M1.4184,502 shs3,917 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Entera Bio Ltd. stock logo
ENTX
Entera Bio
+1.10%+0.55%-5.67%-7.11%-4.19%
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.00%0.00%0.00%0.00%-2.67%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
+0.33%-10.07%-63.76%-46.04%-82.59%
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
+0.38%-3.79%-12.82%-3.44%-20.27%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Entera Bio Ltd. stock logo
ENTX
Entera Bio
4.00
Strong Buy$10.00446.45% Upside
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.00
N/AN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2.33
Hold$7.00620.76% Upside
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest OTLK, ENTX, TTNP, and GENE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/22/2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$21.00 ➝ $8.00
8/29/2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuyNeutral
8/28/2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$3.00
8/28/2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyNeutral
8/27/2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
8/15/2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$3.00
8/11/2025
Entera Bio Ltd. stock logo
ENTX
Entera Bio
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 9/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Entera Bio Ltd. stock logo
ENTX
Entera Bio
$180K464.21N/AN/A$0.23 per share7.96
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
$7.66M0.44N/AN/A$0.25 per share3.06
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/AN/AN/AN/A($3.09) per shareN/A
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
N/AN/AN/AN/A$2.67 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Entera Bio Ltd. stock logo
ENTX
Entera Bio
-$9.54M-$0.26N/AN/AN/A-4,525.11%-77.75%-68.13%11/14/2025 (Estimated)
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
-$7.88MN/A0.00N/AN/AN/AN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$75.37M-$0.57N/AN/AN/AN/AN/A-332.30%N/A
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
-$4.71M-$2.95N/AN/AN/A-108.60%-95.64%N/A

Latest OTLK, ENTX, TTNP, and GENE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q3 2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$0.42-$0.44-$0.02-$0.55$1.66 million$1.51 million
8/14/2025Q2 2025
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
N/A-$0.65N/A-$0.65N/AN/A
8/8/2025Q2 2025
Entera Bio Ltd. stock logo
ENTX
Entera Bio
-$0.11-$0.06+$0.05-$0.06N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Entera Bio Ltd. stock logo
ENTX
Entera Bio
N/AN/AN/AN/AN/A
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
N/AN/AN/AN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/AN/AN/AN/AN/A
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Entera Bio Ltd. stock logo
ENTX
Entera Bio
N/A
10.47
10.47
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.01
0.88
0.83
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/A
0.67
0.54
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
N/A
11.60
11.60

Institutional Ownership

CompanyInstitutional Ownership
Entera Bio Ltd. stock logo
ENTX
Entera Bio
14.11%
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.63%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
11.20%
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
31.49%

Insider Ownership

CompanyInsider Ownership
Entera Bio Ltd. stock logo
ENTX
Entera Bio
10.38%
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
6.46%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
4.80%
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
0.72%
CompanyEmployeesShares OutstandingFree FloatOptionable
Entera Bio Ltd. stock logo
ENTX
Entera Bio
2045.66 million40.92 millionOptionable
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
504.41 million4.53 millionOptionable
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2044.42 million42.29 millionOptionable
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
101.33 million1.32 millionOptionable

Recent News About These Companies

Titan Pharmaceuticals Inc (TTNP) - Investing.com
Titan Pharmaceuticals: Q4 Earnings Snapshot
Titan Pharmaceuticals receives Nasdaq notice of non-compliance
Titan Pharmaceuticals, Inc. (TTNP)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Entera Bio stock logo

Entera Bio NASDAQ:ENTX

$1.83 +0.02 (+1.10%)
Closing price 09/23/2025 04:00 PM Eastern
Extended Trading
$1.86 +0.02 (+1.37%)
As of 09/23/2025 07:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Genetic Technologies stock logo

Genetic Technologies NASDAQ:GENE

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; and Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Oncobiologics stock logo

Oncobiologics NASDAQ:OTLK

$0.97 +0.00 (+0.33%)
Closing price 09/23/2025 04:00 PM Eastern
Extended Trading
$0.98 +0.01 (+1.42%)
As of 06:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Titan Pharmaceuticals stock logo

Titan Pharmaceuticals NASDAQ:TTNP

$4.21 0.00 (0.00%)
Closing price 09/23/2025 03:40 PM Eastern
Extended Trading
$4.29 +0.08 (+1.90%)
As of 04:40 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.